{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:16:04Z","timestamp":1783383364274,"version":"3.54.6"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Beijing Medical Award Foundation","award":["YXJL-2019-0163-0114"],"award-info":[{"award-number":["YXJL-2019-0163-0114"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02167-7","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:53:05Z","timestamp":1778597585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A prospective, open, single-arm clinical trial of fludarabine- cyclophosphamide-porcine anti-lymphocyte globulin conditioning combined with matched sibling donor hematopoietic stem cell transplantation in the treatment of severe aplastic anemia"],"prefix":"10.1007","volume":"26","author":[{"given":"Xiaoyan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2167_CR1","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/s41409-020-0820-x","volume":"55","author":"SH Shin","year":"2020","unstructured":"Shin SH, Park SS, Yoon JH, Yahng SA, Lee SE, Cho BS, et al. Comparison of HLA-matched sibling and unrelated donor transplantation in adult patients with acquired severe aplastic anemia. Bone Marrow Transpl. 2020;55:1570\u20139. https:\/\/doi.org\/10.1038\/s41409-020-0820-x.","journal-title":"Bone Marrow Transpl"},{"key":"2167_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/j.seminhematol.2022.01.002","volume":"59","author":"BA Patel","year":"2022","unstructured":"Patel BA, Townsley DM, Scheinberg P. Immunosuppressive therapy in severe aplastic anemia. Semin Hematol. 2022;59:21\u20139. https:\/\/doi.org\/10.1053\/j.seminhematol.2022.01.002.","journal-title":"Semin Hematol"},{"key":"2167_CR3","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.3324\/haematol.2022.281876","volume":"108","author":"R Devillier","year":"2023","unstructured":"Devillier R, Eikema DJ, Dufour C, Aljurf M, Wu D, Maschan A, et al. Graft-versus-host disease and relapse\/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT. Haematologica. 2023;108:2305\u201315. https:\/\/doi.org\/10.3324\/haematol.2022.281876.","journal-title":"Haematologica"},{"key":"2167_CR4","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.19236","volume":"204","author":"A Kulasekararaj","year":"2024","unstructured":"Kulasekararaj A, Cavenagh J, Dokal I, Foukaneli T, Gandhi S, Garg M, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. Br J Haematol. 2024;204:784\u2013804. https:\/\/doi.org\/10.1111\/bjh.19236.","journal-title":"Br J Haematol"},{"key":"2167_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/bbmt.2001.v7.pm11215697","volume":"7","author":"R Storb","year":"2001","unstructured":"Storb R, Blume KG, O\u2019donnell M R, Chauncey T, Forman SJ, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transpl. 2001;7:39\u201344. https:\/\/doi.org\/10.1053\/bbmt.2001.v7.pm11215697.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2167_CR6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3324\/haematol.2011.050096","volume":"97","author":"J Konopacki","year":"2012","unstructured":"Konopacki J, Porcher R, Robin M, Bieri S, Cayuela JM, Larghero J, et al. Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning. Haematologica. 2012;97:710\u20136. https:\/\/doi.org\/10.3324\/haematol.2011.050096.","journal-title":"Haematologica"},{"key":"2167_CR7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00277-002-0566-0","volume":"81","author":"N Kr\u00f6ger","year":"2002","unstructured":"Kr\u00f6ger N, Zabelina T, Renges H, Kr\u00fcger W, Kordes U, Rischewski J, et al. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin. Ann Hematol. 2002;81:627\u201331. https:\/\/doi.org\/10.1007\/s00277-002-0566-0.","journal-title":"Ann Hematol"},{"key":"2167_CR8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/archinte.1981.00340060066015","volume":"141","author":"JS Gottdiener","year":"1981","unstructured":"Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758\u201363.","journal-title":"Arch Intern Med"},{"key":"2167_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.bbmt.2012.04.014","volume":"18","author":"J Tolar","year":"2012","unstructured":"Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, Mccarty JM, et al. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transpl. 2012;18:1007\u201311. https:\/\/doi.org\/10.1016\/j.bbmt.2012.04.014.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2167_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3324\/haematol.2009.018267","volume":"95","author":"A Bacigalupo","year":"2010","unstructured":"Bacigalupo A, Socie G, Lanino E, Prete A, Locatelli F, Locasciulli A, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica. 2010;95:976\u201382. https:\/\/doi.org\/10.3324\/haematol.2009.018267.","journal-title":"Haematologica"},{"key":"2167_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12185-014-1501-6","volume":"99","author":"M Ashizawa","year":"2014","unstructured":"Ashizawa M, Akahoshi Y, Nakano H, Ugai T, Wada H, Yamasaki R, et al. A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia. Int J Hematol. 2014;99:311\u20137. https:\/\/doi.org\/10.1007\/s12185-014-1501-6.","journal-title":"Int J Hematol"},{"key":"2167_CR12","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00277-012-1462-x","volume":"91","author":"H Kim","year":"2012","unstructured":"Kim H, Lee JH, Joo YD, Bae SH, Hyun MS, Lee JH, et al. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. Ann Hematol. 2012;91:1459\u201369. https:\/\/doi.org\/10.1007\/s00277-012-1462-x.","journal-title":"Ann Hematol"},{"key":"2167_CR13","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3324\/haematol.2009.006916","volume":"94","author":"S Maury","year":"2009","unstructured":"Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Soci\u00e9 G, et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009;94:1312\u20135. https:\/\/doi.org\/10.3324\/haematol.2009.006916.","journal-title":"Haematologica"},{"key":"2167_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00277-024-06028-9","volume":"104","author":"H Zou","year":"2025","unstructured":"Zou H, Yin W, Geng P, Lin L, Nie X, Tao Z, et al. A comprehensive analysis of the major specificities of anti-human T lymphocyte porcine immunoglobulin (p-ATG). Ann Hematol. 2025;104:761\u201371. https:\/\/doi.org\/10.1007\/s00277-024-06028-9.","journal-title":"Ann Hematol"},{"key":"2167_CR15","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3760\/cma.j.issn.0253-2727.2022.04.006","volume":"43","author":"LP Jing","year":"2022","unstructured":"Jing LP, Zhang L, Zhou K, Peng GX, Li Y, Fan HH, et al. [Pharmacokinetic study of anti-human T-cell porcine immunoglobulin combined with cyclosporine A immunosuppressive therapy in patients with severe aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi. 2022;43:300\u20134. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2022.04.006.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2167_CR16","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s00277-015-2308-0","volume":"94","author":"J Wei","year":"2015","unstructured":"Wei J, Huang Z, Guo J, Zhang Y, Wang C, Zhu X, et al. Porcine antilymphocyte globulin (p-ALG) plus cyclosporine A (CsA) treatment in acquired severe aplastic anemia: a retrospective multicenter analysis. Ann Hematol. 2015;94:955\u201362. https:\/\/doi.org\/10.1007\/s00277-015-2308-0.","journal-title":"Ann Hematol"},{"key":"2167_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/ejh.12590","volume":"96","author":"M Chen","year":"2016","unstructured":"Chen M, Liu C, Zhuang J, Zou N, Xu Y, Zhang W, et al. Long-term follow-up study of porcine anti-human thymocyte immunoglobulin therapy combined with cyclosporine for severe aplastic anemia. Eur J Haematol. 2016;96:291\u20136. https:\/\/doi.org\/10.1111\/ejh.12590.","journal-title":"Eur J Haematol"},{"key":"2167_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/17474086.2024.2350527","volume":"17","author":"S Xu","year":"2024","unstructured":"Xu S, Xiao Y, Liang X, Lu Y, Deng M. The long-term outcomes and safety of severe aplastic anemia treated with porcine antilymphocyte globulin plus cyclosporine, with or without thrombopoietin receptor agonists: a double-center retrospective study. Expert Rev Hematol. 2024;17:181\u20138. https:\/\/doi.org\/10.1080\/17474086.2024.2350527.","journal-title":"Expert Rev Hematol"},{"key":"2167_CR19","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/jco.1988.6.10.1562","volume":"6","author":"SI Bearman","year":"1988","unstructured":"Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562\u20138. https:\/\/doi.org\/10.1200\/jco.1988.6.10.1562.","journal-title":"J Clin Oncol"},{"key":"2167_CR20","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant.(1995)15:825-8."},{"key":"2167_CR21","first-page":"250","volume":"28","author":"KM Sullivan","year":"1991","unstructured":"Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250\u20139.","journal-title":"Semin Hematol"},{"key":"2167_CR22","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/sj.bmt.1705165","volume":"36","author":"A Bacigalupo","year":"2005","unstructured":"Bacigalupo A, Locatelli F, Lanino E, Marsh J, Soci\u00e9 G, Maury S, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transpl. 2005;36:947\u201350. https:\/\/doi.org\/10.1038\/sj.bmt.1705165.","journal-title":"Bone Marrow Transpl"},{"key":"2167_CR23","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/bmt.2016.171","volume":"51","author":"SH Shin","year":"2016","unstructured":"Shin SH, Jeon YW, Yoon JH, Yahng SA, Lee SE, Cho BS, et al. Comparable outcomes between younger (\u2a7d40 years) and older (>\u200940 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning. Bone Marrow Transpl. 2016;51:1456\u201363. https:\/\/doi.org\/10.1038\/bmt.2016.171.","journal-title":"Bone Marrow Transpl"},{"key":"2167_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00277-014-2279-6","volume":"94","author":"L Liu","year":"2015","unstructured":"Liu L, Ding L, Hao L, Zhang X, Li X, Zhang L, et al. Efficacy of porcine antihuman lymphocyte immunoglobulin compared to rabbit antithymocyte immunoglobulin as a first-line treatment against acquired severe aplastic anemia. Ann Hematol. 2015;94:729\u201337. https:\/\/doi.org\/10.1007\/s00277-014-2279-6.","journal-title":"Ann Hematol"},{"key":"2167_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bbmt.2017.10.007","volume":"24","author":"X Chen","year":"2018","unstructured":"Chen X, Wei J, Huang Y, He Y, Yang D, Zhang R, et al. Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia. Biol Blood Marrow Transpl. 2018;24:86\u201390. https:\/\/doi.org\/10.1016\/j.bbmt.2017.10.007.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2167_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-3-031-84988-6_4","volume":"1475","author":"S Hong","year":"2025","unstructured":"Hong S, Horwitz ME. Graft Source Choice. Adv Exp Med Biol. 2025;1475:57\u201375. https:\/\/doi.org\/10.1007\/978-3-031-84988-6_4.","journal-title":"Adv Exp Med Biol"},{"key":"2167_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bbmt.2010.06.014","volume":"17","author":"JW Lee","year":"2011","unstructured":"Lee JW, Cho BS, Lee SE, Eom KS, Kim YJ, Kim HJ, et al. The Outcome of Unrelated Hematopoietic Stem Cell Transplants with Total Body Irradiation (800\u00a0cGy) and Cyclophosphamide (120\u00a0mg\/kg) in Adult Patients with Acquired Severe Aplastic Anemia. Biol Blood Marrow Transpl. 2011;17:101\u20138. https:\/\/doi.org\/10.1016\/j.bbmt.2010.06.014.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2167_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ajh.21355","volume":"84","author":"S Okuda","year":"2009","unstructured":"Okuda S, Terasako K, Oshima K, Sato M, Nakasone H, Kako S, et al. Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function. Am J Hematol. 2009;84:167\u20139. https:\/\/doi.org\/10.1002\/ajh.21355.","journal-title":"Am J Hematol"},{"key":"2167_CR29","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/bloodadvances.2019000722","volume":"3","author":"N Bejanyan","year":"2019","unstructured":"Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, et al. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3:3123\u201331. https:\/\/doi.org\/10.1182\/bloodadvances.2019000722.","journal-title":"Blood Adv"},{"key":"2167_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ajh.25693","volume":"95","author":"S Kako","year":"2020","unstructured":"Kako S, Kanda Y, Onizuka M, Aotsuka N, Usuki K, Tachibana T, et al. Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. Am J Hematol. 2020;95:251\u20137. https:\/\/doi.org\/10.1002\/ajh.25693.","journal-title":"Am J Hematol"},{"key":"2167_CR31","first-page":"152","volume":"15","author":"XH Zhang","year":"2007","unstructured":"Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Lu DP. [Pharmacokinetics of antithymocyte globulin in recipients under-going HLA partially matched hematopoietic stem cell transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007;15:152\u20135.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2167_CR32","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/ejh.12584","volume":"96","author":"X Ma","year":"2016","unstructured":"Ma X, Wang J, Zhang W, Cao X, Chen Y, He A, et al. Comparison of porcine anti-human lymphocyte globulin and rabbit anti-human thymocyte globulin in the treatment of severe aplastic anemia: a retrospective single-center study. Eur J Haematol. 2016;96:260\u20138. https:\/\/doi.org\/10.1111\/ejh.12584.","journal-title":"Eur J Haematol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02167-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02167-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02167-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:44:58Z","timestamp":1783381498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02167-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2167"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02167-7","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Union Hospital, Huazhong University of Science and Technology, and was conducted in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"All patients gave written informed consent before participating in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent Statement"}}],"article-number":"250"}}